Barry H Trachtenberg1, Andrea M Cordero-Reyes2, Molham Aldeiri3, Paulino Alvarez2, Arvind Bhimaraj4, Guha Ashrith4, Barbara Elias5, Erik E Suarez2, Brian Bruckner4, Matthias Loebe4, Richard L Harris6, J Yi Zhang7, Guillermo Torre-Amione8, Jerry D Estep4. 1. Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas; Houston Methodist JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, Texas. Electronic address: btrachtenberg@houstonmethodist.org. 2. Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas. 3. Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas; Department of Cardiology, University of Texas Medical Branch, Galveston, Texas. 4. Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas; Houston Methodist JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, Texas. 5. Houston Methodist JC Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, Texas. 6. Department of Infectious Diseases, Houston Methodist, Houston, Texas. 7. Department of Neurological Surgery, Houston Methodist, Houston, Texas. 8. Houston Methodist DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, Texas; Cátedra de Cardiologia y Medicina Vascular, Tecnológico de Monterrey, Monterrey, México.
Abstract
BACKGROUND: Common adverse events in patients supported with Continuous-flow left ventricular assist devices (CF-LVAD) include infections and cerebrovascular accidents (CVA). Some studies have suggested a possible association between blood stream infection (BSI) and CVA. METHODS AND RESULTS: Medical records of patients who received Heartmate II (HMII) CF-LVADs in 2008-2012 at a single center were reviewed. CVA was categorized as either hemorrhagic (HCVA) or ischemic (ICVA). BSI was divided into persistent (pBSI) and nonpersistent (non-pBSI). pBSI was defined as BSI with the same organism on repeated blood culture >72 hours from initial blood culture despite antibiotics. Univariate and multivariate analyses were performed to determine predictors. A total of 149 patients had HMII implanted; 76% were male, and the overall mean age was 55.4 ± 13 years. There were a total of 19 (13%) patients who had CVA (7 HCVA and 12 ICVA) at a median of 295 days (range 5-1,096 days) after implantation. There were a total of 28 (19%) patients with pBSI and 17 (11%) patients with non-pBSI. Patients with pBSI had a trend toward greater BMI (31 kg/m(2) vs 27 kg/m(2); P = .09), and longer duration of support (1,019 d vs 371 d; P < .001) compared with those with non-pBSI. Persistent BSI was associated with an increased risk of mortality and with all-cause CVA on multivariate analysis (odds ratio [OR] 5.97; P = .003) as well as persistent Pseudomonas aeruginosa infection (OR 4.54; P = .048). CONCLUSIONS: Persistent BSI is not uncommon in patients supported by CF-LVAD and is highly associated with all-cause CVA and increased all-cause mortality.
BACKGROUND: Common adverse events in patients supported with Continuous-flow left ventricular assist devices (CF-LVAD) include infections and cerebrovascular accidents (CVA). Some studies have suggested a possible association between blood stream infection (BSI) and CVA. METHODS AND RESULTS: Medical records of patients who received Heartmate II (HMII) CF-LVADs in 2008-2012 at a single center were reviewed. CVA was categorized as either hemorrhagic (HCVA) or ischemic (ICVA). BSI was divided into persistent (pBSI) and nonpersistent (non-pBSI). pBSI was defined as BSI with the same organism on repeated blood culture >72 hours from initial blood culture despite antibiotics. Univariate and multivariate analyses were performed to determine predictors. A total of 149 patients had HMII implanted; 76% were male, and the overall mean age was 55.4 ± 13 years. There were a total of 19 (13%) patients who had CVA (7 HCVA and 12 ICVA) at a median of 295 days (range 5-1,096 days) after implantation. There were a total of 28 (19%) patients with pBSI and 17 (11%) patients with non-pBSI. Patients with pBSI had a trend toward greater BMI (31 kg/m(2) vs 27 kg/m(2); P = .09), and longer duration of support (1,019 d vs 371 d; P < .001) compared with those with non-pBSI. Persistent BSI was associated with an increased risk of mortality and with all-cause CVA on multivariate analysis (odds ratio [OR] 5.97; P = .003) as well as persistent Pseudomonas aeruginosa infection (OR 4.54; P = .048). CONCLUSIONS: Persistent BSI is not uncommon in patients supported by CF-LVAD and is highly associated with all-cause CVA and increased all-cause mortality.
Authors: Deepak Acharya; Renzo Loyaga-Rendon; Charity J Morgan; Kara A Sands; Salpy V Pamboukian; Indranee Rajapreyar; William L Holman; James K Kirklin; José A Tallaj Journal: JACC Heart Fail Date: 2017-10 Impact factor: 12.035
Authors: Christopher A Wrobel; Mark H Drazner; Colby R Ayers; David D Pham; Ricardo M La Hoz; Justin L Grodin; Sonia Garg; Pradeep P A Mammen; Robert M Morlend; Faris Araj; Alpesh A Amin; William K Cornwell; Jennifer T Thibodeau Journal: J Investig Med Date: 2019-01-29 Impact factor: 2.895
Authors: Mike Lee; Hirokazu Akashi; Tomoko S Kato; Hiroo Takayama; Christina Wu; Katherine Xu; Elias Collado; Matthew P Weber; Peter J Kennel; Danielle L Brunjes; Ruiping Ji; Yoshifumi Naka; Isaac George; Donna Mancini; Maryjane Farr; P Christian Schulze Journal: J Heart Lung Transplant Date: 2016-01-06 Impact factor: 10.247
Authors: Pouya Tahsili-Fahadan; David R Curfman; Albert A Davis; Noushin Yahyavi-Firouz-Abadi; Lucia Rivera-Lara; Michael E Nassif; Shane J LaRue; Gregory A Ewald; Allyson R Zazulia Journal: Neurocrit Care Date: 2018-10 Impact factor: 3.210